The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease
Background/Purpose: Bisphosphonates (BPs) impact on the survival and cardiovascular safety of osteoporosis patients after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) was evaluated. Methods: A nationwide epidemiological study was conducted using the Taiwan National Health Insurance R...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664620306148 |
id |
doaj-d560fec73d484bedb302cedc345362dd |
---|---|
record_format |
Article |
spelling |
doaj-d560fec73d484bedb302cedc345362dd2021-10-09T04:36:50ZengElsevierJournal of the Formosan Medical Association0929-66462021-11-011201119571966The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular diseaseShu-Ting Wu0Jung-Fu Chen1Chia-Jen Tsai2Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanCorresponding author. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, 123 Ta-Pei Road, Niao-sung District, Kaohsiung City, 833, Taiwan.; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanBackground/Purpose: Bisphosphonates (BPs) impact on the survival and cardiovascular safety of osteoporosis patients after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) was evaluated. Methods: A nationwide epidemiological study was conducted using the Taiwan National Health Insurance Research Database from 2000 to 2010. From the 1456 osteoporosis patients with previous ACS or AIS, mortality and cardiovascular safety was compared between 464 patients who used BPs and 464 patients who did not. Primary outcomes included all-cause mortality, and major adverse cardiovascular events. Results: The BPs group had a lower risk of all-cause mortality than the control group after the 8-year follow-up (HR, 0.64; 95% CI, 0.46–0.88; P = 0.006). The risks of myocardial infarction, ischemic stroke, cardiovascular death, hospitalization for heart failure or other causes of mortality were similar across groups. However, there was a higher risk of hospitalization for atrial fibrillation in the BPs group than the control group (HR, 1.76; 95% CI, 1.26–2.46; P = 0.001). Conclusion: Among osteoporosis patients after ACS or AIS, BPs use was associated with a reduced risk of all-cause mortality. However, patients with previous cardiovascular disease who received BP treatment should be careful about the risk of atrial fibrillation.http://www.sciencedirect.com/science/article/pii/S0929664620306148BisphosphonateOsteoporosisCardiovascular outcomeMortality riskAtrial fibrillation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shu-Ting Wu Jung-Fu Chen Chia-Jen Tsai |
spellingShingle |
Shu-Ting Wu Jung-Fu Chen Chia-Jen Tsai The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease Journal of the Formosan Medical Association Bisphosphonate Osteoporosis Cardiovascular outcome Mortality risk Atrial fibrillation |
author_facet |
Shu-Ting Wu Jung-Fu Chen Chia-Jen Tsai |
author_sort |
Shu-Ting Wu |
title |
The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
title_short |
The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
title_full |
The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
title_fullStr |
The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
title_full_unstemmed |
The impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
title_sort |
impact of bisphosphonates on mortality and cardiovascular risk among osteoporosis patients after cardiovascular disease |
publisher |
Elsevier |
series |
Journal of the Formosan Medical Association |
issn |
0929-6646 |
publishDate |
2021-11-01 |
description |
Background/Purpose: Bisphosphonates (BPs) impact on the survival and cardiovascular safety of osteoporosis patients after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) was evaluated. Methods: A nationwide epidemiological study was conducted using the Taiwan National Health Insurance Research Database from 2000 to 2010. From the 1456 osteoporosis patients with previous ACS or AIS, mortality and cardiovascular safety was compared between 464 patients who used BPs and 464 patients who did not. Primary outcomes included all-cause mortality, and major adverse cardiovascular events. Results: The BPs group had a lower risk of all-cause mortality than the control group after the 8-year follow-up (HR, 0.64; 95% CI, 0.46–0.88; P = 0.006). The risks of myocardial infarction, ischemic stroke, cardiovascular death, hospitalization for heart failure or other causes of mortality were similar across groups. However, there was a higher risk of hospitalization for atrial fibrillation in the BPs group than the control group (HR, 1.76; 95% CI, 1.26–2.46; P = 0.001). Conclusion: Among osteoporosis patients after ACS or AIS, BPs use was associated with a reduced risk of all-cause mortality. However, patients with previous cardiovascular disease who received BP treatment should be careful about the risk of atrial fibrillation. |
topic |
Bisphosphonate Osteoporosis Cardiovascular outcome Mortality risk Atrial fibrillation |
url |
http://www.sciencedirect.com/science/article/pii/S0929664620306148 |
work_keys_str_mv |
AT shutingwu theimpactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease AT jungfuchen theimpactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease AT chiajentsai theimpactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease AT shutingwu impactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease AT jungfuchen impactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease AT chiajentsai impactofbisphosphonatesonmortalityandcardiovascularriskamongosteoporosispatientsaftercardiovasculardisease |
_version_ |
1716830721037828096 |